




**Transfusion Reaction
Module 5**




**Transfusion Reaction
Reporting and Surveillance
Case Studies**



BC Provincial Blood Coordinating Office
A program of the Provincial Health Services Authority



**BC Transfusion Medicine
Advisory Group**




Speaker

Dr. Louis Wadsworth
MB FRCP(C) FRC Path
Clinical Professor, Department of Pathology,
University of British Columbia

Disclosure:
Dr. Wadsworth states that he has no conflict of
interest relating to industry.


2011201 2



Contents of Module 5

- Goals and Objectives
- TMAG Recommendations
- Transfusion Reaction chain of events
- Surveillance Reports
- 2010 Transfusion Reaction Toolkit
- Transfusion Reaction Report Form
- Case studies

2011201 3




Goal and Objectives of Module 5

Goals are to:

- orient the pathologist to transfusion reaction reporting
- ensure that pathologists have the knowledge to report transfusion reactions using the provincial transfusion reaction reporting template
- explain the need for provincial and national data surveillance

2011201 4





Objectives of Module 5

On completion of this module, you should be able to:

- identify essential elements of the BC TR reporting system
- identify the components of the Transfusion Reaction Toolkit
- use the provincial model Transfusion Reaction Report (TRR) form
- report the results of a transfusion reaction investigation to meet provincial model surveillance requirements

2011201 5



Key Points - Module 1

- Stop all transfusions as soon as a reaction is suspected.
- All TR must be reported, report what the reaction is (*not what it is not*)
- For all suspected TR, a bedside check should verify that the correct patient is receiving the correct component/product, correctly labelled and infused at the correct flow rate.
- Signs and symptoms of different transfusion reaction types overlap
▲ difficult to distinguish clinically the type of reaction occurring
- A laboratory investigation is required to determine if the signs/symptoms are related to the transfusion.
- A serious TR requires prompt action.
- Delayed reactions require laboratory investigation. These investigations and reports are often initiated by the laboratory.

2011201 6



| Year | TR Surveillance Timeline in BC |
|-------------|---|
| 1998 | Krever Commission recommendation |
| 1999-2004 | National Working Group develops and pilots TTISS BC – pilots with 4 facilities |
| 2004 | Additional BC sites as a result of education |
| 2009 - 2011 | BC TTISS Renewal project - development phase |
| 2011 - 2013 | Implementation of BC TTISS Renewal project in all BC facilities |


2011201 8

BC TTISS – Renewal

- 2009-2010, BC TMAG endorsed a review and standardization of processes related to TR.
- Multidisciplinary teams (nurse, TM-MD and technologist) developed and released provincial model documents that merge standardized provincial best practice with Health Canada TTISS reporting elements for:
 - bedside recognition and reporting of TR
 - laboratory investigation process
 - pathologist interpretation and conclusion

Collectively these documents have been named the Transfusion Reaction Toolkit.


2011201 9



BC TTISS
Transfusion Reaction Toolkit:

- Represents provincial best practices
 - developed and reviewed by Health Authority representatives to TMAG, NRG and TRG
 - approved by TMAG
- Includes BC provincial model documents
 - for implementation by Health Authority TMS leaders
- Released to HAs in August 2010
- Posted at the PBCO website


2011201 10



BC TTISS
Transfusion Reaction Toolkit:

| | |
|--------------------------|---|
| Nurse/ Transfusionist | Quick Reference Guide – Response to Transfusion Reaction Transfusion Reaction Report form |
| Technologist | Transfusion Reaction Investigation Process and Procedures Training & competence documents |
| Pathologist | Transfusion Reaction Report form Transfusion Medicine Medical Policy Manual Section 11 – Appendix D, Table 11.4 Recommendations for Pathologist Comments – Transfusion Reaction Report |

2011201 11




Reporting to TMS- WHY?

Reporting:

- ensures appropriate patient care
 - triggers TR investigations
 - provides recommendations for future transfusions
 - ensures the continuity of patient transfusion history
- comprises an essential component of transfusion safety
 - provides surveillance data for Transfusion Committees and relevant quality committees
 - identifies potential problems and focuses development of quality improvement initiatives
 - fulfills provincial and national accreditation standards/requirements

2011201 12



Reporting


To Patient Chart/Electronic Record:

- communicates the results of the TR investigation
- provides recommendations for future transfusions
- raises awareness about the adverse effects of transfusion

To PBCO:

- facilitates BC TTISS provincial and TTISS national surveillance
- provides provincial data to base improvements to patient safety and transfusion best practice.


2011201 13




Mandate for TR reporting?

| Agency/Body | Section | Details |
|-------------------------|--------------------------------|--|
| CAN/CSA Z902-10 | 18 | Document, report, evaluate and follow-up ALL adverse reactions related to transfusion |
| DAP - BC | 11 | Document, promptly report, evaluate and follow-up ALL adverse events related to blood transfusion |
| Accreditation Canada | 22.0 BB and TS Standards | "The transfusion service identifies, reports, evaluates, and follows-up on all adverse events." – in reference to transfusions |
| CSTM Standards | 7.2 | Document, report, evaluate and follow-up ALL adverse reactions related to transfusion |

2011201 14




TMAG Recommendations:



- All TR should be reported to the Transfusion Medicine Service
- All TR reports should be sent to PBCO.
– *Except "Not a Transfusion Reaction" cases*
- Non-complex TR reports should be reviewed, concluded and reported internally within 10 working days of the notification of the reaction

2011201 15




Recapping from Module 1:

Triggers for Contact

Roles in TR Investigation


2011201 16



Clinical Staff immediately phone the TMS/lab when:

- there is a patient/component/product identity error
- the patient has any of the following:
 - new onset red/brown urine
 - sudden onset of hypoxemia
 - SpO2 <90% on RA or
 - PaO2 < 60mm Hg on RA or
 - PaO2/FiO2 ratio ≤ 300)
 - sudden onset of hypotension
 - ≥30 mm Hg drop in systolic BP and
 - systolic BP below 80 mm Hg
- suspected bacterial contamination of component/product

2011201 17



Laboratory Staff immediately phone the on-duty pathologist when:

- they receive a report of a TR where there is:
 - recipient or component/product identity error
 - suspected bacterial contamination of the component/product
 - sudden onset of hypoxemia
 - sudden onset of hypotension
 - new onset of red/brown urine (if hemoglobinuria is proven)
- the transfusion reaction investigation shows:
 - abnormal results in the Primary Investigation
 - additional component/product is requested and the investigation is not complete

2011201 18

Roles in Transfusion Reaction Investigation

| | |
|----------------|---|
| clinical staff | <ul style="list-style-type: none"> initiates TR Investigation promptly manages the clinical care orders X-rays & cultures on recipient as prescribed |
| technologist | <ul style="list-style-type: none"> investigates the Transfusion Reaction performs examinations contacts TM pathologist coordinates results for pathologist to review sends out completed reports promptly to chart, physician(s) and external agencies |
| pathologist | <ul style="list-style-type: none"> provides consultations for TMS/Lab and clinical staff provides recommendations for future transfusions reviews S/S and lab results to reach a "conclusion" of report within 10 working days contacts blood supplier, if applicable |

2011201 19

REPORTING

2011201 20

Reporting

| To | Document |
|------------------------------|---|
| TMS/lab | TRR form or phone call from clinical care area |
| Patient chart | TRR investigation conclusion |
| PBCO, CBS, Manufacturer | <ul style="list-style-type: none"> TRR form with pathologist's conclusion > PBCO exports non-nominal data to HC |
| CBS for possible TRALI cases | TRR form and pathologist's conclusion PLUS CBS TRALI form |

2011201 21

TMS/Lab External Reporting (1 of 2)

| What | Where | When |
|-------------------|-------------------|---|
| all reactions | PBCO | reaction investigation conclusion |
| serious reactions | CBS/ Manufacturer | promptly* when reaction investigation concluded |


*For suspected bacterial contamination facilities must report to CBS/manufacturer within 24 hrs


2011201 22

TMS/Lab External Reporting (2 of 2)

| Condition | What | Where | When |
|---|------------------------|-------------------|---|
| Death | component | CBS | within 24 hours of suspected linkage & at investigation conclusion |
| | plasma protein product | Manufacturer | as soon as linkage is suspected & at investigation conclusion |
| Serious reactions due to product quality issues | component | CBS/ Manufacturer | as soon as linkage is suspected & at investigation conclusion (within 24 hours for suspected bacterial contamination) |
| | plasma protein product | Manufacturer | as soon as linkage is suspected & at investigation conclusion |

2011201 23






Tranfusion Reaction Report Form

Provincial Model TRRF

2011201 25




Tranfusion Reaction Report form (TRR)

BC Model document contains 2 pages:
Page 1 is used by nurse/transfusionist to report the details of the:
 - recipient and transfusion
 - signs and symptoms of the transfusion reaction
 - clinical management of reaction

Page 2 is used by technologist/pathologist to:
 • summarize TR investigation results
 • record pathologist final conclusion providing :
 - type
 - relationship of reaction to transfusion
 - severity
 - outcome
 • record recommendations for future transfusions

2011201 26



Tranfusion Reaction Report (TRR) form page 1

2011201

| Health Authority LOGO | TRANSFUSION REACTION REPORT | Patient Demographics |
|--|-----------------------------------|----------------------|
| <input type="checkbox"/> Family <input type="checkbox"/> Facility <input type="checkbox"/> Facility <input type="checkbox"/> Facility <input type="checkbox"/> Facility <input type="checkbox"/> Facility <input type="checkbox"/> Facility <input type="checkbox"/> Facility | | |
| - Organism: _____ - Indication for Transfusion: _____ - Category: <input type="checkbox"/> Hemorrhagic <input type="checkbox"/> Coagulation <input type="checkbox"/> Hematologic <input type="checkbox"/> Surgical <input type="checkbox"/> Obstetric/Gynecologic <input type="checkbox"/> Trauma <input type="checkbox"/> Medical | | |
| II. Recipient and Donor Information Recipient Name: _____ Recipient ID: _____ Recipient Age: _____ Recipient Sex: _____ Recipient Race: _____ Recipient Religion: _____ Recipient Ethnicity: _____ Recipient Marital Status: _____ Recipient Occupation: _____ Recipient Address: _____ Recipient City: _____ Recipient State: _____ Recipient Zip: _____ Recipient Phone: _____ Recipient Email: _____ Recipient Date of Birth: _____ Recipient Blood Type: _____ Recipient Rh Factor: _____ Recipient Transfusion History: _____ Recipient Allergies: _____ Recipient Current Medications: _____ Recipient Current Illnesses: _____ Recipient Current Treatments: _____ Recipient Current Procedures: _____ Recipient Current Tests: _____ Recipient Current Imaging: _____ Recipient Current Pathology: _____ Recipient Current Microbiology: _____ Recipient Current Serology: _____ Recipient Current Hematology: _____ Recipient Current Chemistry: _____ Recipient Current Immunology: _____ Recipient Current Infectious Disease: _____ Recipient Current Oncology: _____ Recipient Current Cardiology: _____ Recipient Current Pulmonology: _____ Recipient Current Nephrology: _____ Recipient Current Endocrinology: _____ Recipient Current Rheumatology: _____ Recipient Current Neurology: _____ Recipient Current Psychiatry: _____ Recipient Current Dermatology: _____ Recipient Current Ophthalmology: _____ Recipient Current Otolaryngology: _____ Recipient Current Plastic Surgery: _____ Recipient Current Orthopedics: _____ Recipient Current Urology: _____ Recipient Current Gynecology: _____ Recipient Current Urology: _____ Recipient Current Pediatrics: _____ Recipient Current Geriatrics: _____ Recipient Current Palliative Care: _____ Recipient Current Hospice: _____ Recipient Current End-of-Life Care: _____ Recipient Current Organ Donation: _____ Recipient Current Stem Cell Donation: _____ Recipient Current Organ Transplant: _____ Recipient Current Bone Marrow Transplant: _____ Recipient Current Cord Blood Transplant: _____ Recipient Current Hematopoietic Stem Cell Transplant: _____ Recipient Current Allogeneic Hematopoietic Stem Cell Transplant: _____ Recipient Current Autologous Hematopoietic Stem Cell Transplant: _____ Recipient Current Syngeneic Hematopoietic Stem Cell Transplant: _____ Recipient Current Umbilical Cord Blood Transplant: _____ Recipient Current Placental Cord Blood Transplant: _____ Recipient Current Bone Marrow Transplant: _____ Recipient Current Cord Blood Transplant: _____ Recipient Current Hematopoietic Stem Cell Transplant: _____ Recipient Current Allogeneic Hematopoietic Stem Cell Transplant: _____ Recipient Current Autologous Hematopoietic Stem Cell Transplant: _____ Recipient Current Syngeneic Hematopoietic Stem Cell Transplant: _____ Recipient Current Umbilical Cord Blood Transplant: _____ Recipient Current Placental Cord Blood Transplant: _____ | | |

Page 2 – Section 7c Pathologist Conclusion

INCIDENT: error/accident occurred that is related to this reaction.

NO TRANSFUSION REACTION: problem was not related to the product or the transfusion process, likely due to patient condition or other factors

TRALI – follows CBS criteria

OTHER: reaction occurred, but unable to classify as any type, including Unknown

UNKNOWN: cannot classify reaction, but is new & unexpected AND of clinical significance

2011201 31

Page 2 – Section 7d Relationship, Severity & Outcome

SEVERITY of reaction

RELATIONSHIP of reaction to component/product

OUTCOME of reaction

Relationship to Death – if Death was the outcome

Notification

2011201 32


Page 2 – Section 8 Pathologist Comments & Recommendations

8. Pathologist Comments and Recommendations

Free text space to write conclusion/advice for clinician and recommendations for future transfusions, if indicated.

TMAG recommendations for standardized reporting comments are found in the Transfusion Reaction Toolkit and in Section 11, Appendix D, Table 11.4 of the TM-Medical Policy Manual.


2011201 33



When to use the “Unknown” category for a TR:

- When the recipient has experienced a clinically significant reaction that cannot be classified and represents something new and unexpected
 - Eg red eye syndrome
- Such circumstances are extremely rare
- “Unknowns” are reported to national TTISS


2011201 34




When to use the “Other” category for a TR:

- When the recipient has experienced any other type of transfusion reaction not already described in the surveillance categories
 - Examples:
 - Severe electrolyte imbalance as would occur using a stored irradiated red cell unit
 - Atypical pain syndrome (pain not usually associated with receiving a blood transfusion)

2011201 35




Transfusion Reaction



Case Studies

2011201 36



Case Study 1


Clinical History:

- 53 year old oncology inpatient, multiply transfused, received 1 dose of platelets,
- S/S include:
 - Pre -Tx Temp - 36.9°C
 - Post -Tx Temp - 38.5°C (1.6 °C rise in temperature)
 - chills

Lab investigation details:

- clerical check, visual check of unit and post-transfusion samples - OK
- DAT is negative
- Culture is not indicated

2011201 37




Case Study 1 – Section 7 results

(1 of 2)

| | Heading | Result |
|----|-----------------------------|----------------------|
| 7c | Pathologist Conclusion | FNH |
| 7d | Relationship to transfusion | probable |
| 7d | Severity | Grade 1 (non-severe) |
| 7d | Outcome | Minor (no sequelae) |
| 7d | Status of Investigation | Concluded |

2011201 38



Case Study 1 – Section 8 results

(2 of 2)

| | Heading | Result |
|---|---------------------|--|
| 8 | Pathologist comment | <p>Pathologist Recommended Comments</p> <p><i>Based on a review of the patient's history, clinical and serological findings the patient's symptoms are most consistent with a febrile nonhemolytic transfusion reaction (FNHTR).</i></p> <p><i>For recurrent febrile nonhemolytic transfusion reactions, premedication with an antipyretic may be considered, but is not supported by literature evidence. Consultation with a Transfusion Medicine Pathologist may be helpful if the patient experiences recurrent febrile reactions.</i></p> |

2011201 39

Case Study 2

Clinical History:
 12 year old multiply transfused patient with β thalassemia major develops chills and nausea 2 hours after infusion of a unit of rbc.

| Vital Signs | Temperature | BP |
|-------------|-------------|--------|
| Pre-Tx | 36.7 | 100/65 |
| Post-Tx | 36.9 | 105/73 |

Lab investigation details:

- clerical check, visual check of unit and post-transfusion samples - OK
- DAT is negative

2011201 40

Case Study 2 – Section 7 results

(1 of 2)

| | Heading | Result |
|----|------------------------|----------------------|
| 7c | Pathologist Conclusion | FNH |
| 7d | Relationship | probable |
| 7d | | Grade 1 (non-severe) |
| 7d | | minor (no sequelae) |
| 7d | Investigation | Concluded |

You will recall from Module 3 that a FNHTR despite the name does not always result in a temperature rise

2011201 41

Case Study 2 – Section 8 results

(2 of 2)


| | Heading | Result |
|---|---------------------|----------------------------------|
| 8 | Pathologist comment | Pathologist Recommended Comments |

Based on a review of the patient's history, clinical and serological findings the patient's symptoms are most consistent with a febrile nonhemolytic transfusion reaction (FNHTR).

For recurrent FNHTR, premedication with an antipyretic may be considered, but is not supported by literature evidence.

Consultation with a Transfusion Medicine Pathologist may be helpful if the patient experiences recurrent febrile reactions.


2011201 42



Case study 3

- A 60 yr old oncology patient with septicemia and a fluctuating temperature receives a dose of platelets.
- During the infusion the temperature rises from 37 to 38.1C. No other symptoms/signs are reported.
- Laboratory testing and checks are negative
- There is no evidence that this is a TR and temperature change probably reflects patient's underlying condition

2011201 43




Case Study 3 – Section 7 results

(1 of 2)

| | Heading | Result |
|----|-----------------------------|-------------------------|
| 7c | Pathologist Conclusion | No transfusion reaction |
| 7d | Relationship to transfusion | Doubtful |
| 7d | Severity | N/A |
| 7d | Outcome | N/A |
| 7d | Status of Investigation | Concluded |

2011201 44



Case Study 3 – Section 8 results


(2 of 2)

| | Heading | Result |
|---|---------------------|----------------------------------|
| 8 | Pathologist comment | Pathologist Recommended Comments |

This is not a Transfusion Reaction. Patient's fever is explained by the underlying condition and coincidental to transfusion.

This case is not reported to PBCO

2011201 45



Case Study 4


Page 1 relevant details:

Frozen plasma is ordered for a post-operative patient with severe bleeding. During transfusion the patient develops itching and hives over the arms and trunk. Transfusion is stopped and antihistamine is given

Lab investigation details:

The bedside nurse realises, during the identity check, that the infused product is platelets rather than plasma. No lab investigation is done but the technologist confirms that platelets had been issued rather than plasma.

2011201 46




Case Study 4 – Section 7 results

(1 of 2)

| | Heading | Result |
|----|-----------------------------|--------------------------------|
| 7c | Incident | YES and product related |
| 7c | Pathologist Conclusion | Allergic |
| 7d | Relationship to transfusion | Probable |
| 7d | Severity | Grade 1 (non-severe) |
| 7d | Outcome | Minor (no sequelae) |
| 7d | Status of Investigation | Concluded |

2011201 47



Case Study 4 – Section 8 results

(2 of 2)


| | Heading | Result |
|---|---------------------|----------------------------------|
| 8 | Pathologist comment | Pathologist Recommended Comments |

Based on a review of the patient's history and clinical findings, the patient's symptoms are most consistent with an allergic transfusion reaction.

For recurrent allergic transfusion reactions, premedication with an antihistamine may be considered, but is not supported by literature evidence. Urgent consultation with a Transfusion Medicine Pathologist is suggested if the patient experiences a severe allergic or anaphylactic reaction.

BUT the nursing unit and laboratory followed up with incident reports. It is important to realize that the patient may not have suffered a TR if the correct product had been issued.


2011201 48



Case study 5

- A 12 year old girl with sickle cell anemia (SCA) with no detectable rbc alloantibodies receives a red cell transfusion (Rh, K phenotype matched) prior to a laparoscopic cholecystectomy. Pre Tx Hb 73g/L
- 12 days post transfusion she is readmitted with lower back pain, headache and Hb of 52g/L
- Further rbc transfusion is ordered but
 - Anti S is detected
 - DAT negative
 - LDH 2275 u/L (380-770) (the pre op was LDH 1556)

2011201 49




Case Study 5 – Section 7 results

(1 of 2)

| | Heading | Result |
|----|-----------------------------|--------------------------|
| 7c | Pathologist Conclusion | Delayed Hemolytic TR |
| 7d | Relationship to transfusion | Probable |
| 7d | Severity | Severe |
| 7d | Outcome | Major/long term sequelae |
| 7d | Status of Investigation | Concluded |

2011201 50



Case Study 5 – Section 8 results


(2 of 2)

| | Heading | Result |
|---|---------------------|----------------------------------|
| 8 | Pathologist comment | Pathologist Recommended Comments |

*Despite the negative DAT this patient has had a DHTR. This type of reaction is not uncommon in patients with SCA who have a high rate of sensitization since they receive blood largely collected from an ethnically different donor base. All future rbc transfusions for this patient **must** be S antigen negative.*

In patients with SCA, DHTR must be differentiated from episodes of SCA related hyperhemolysis which can be triggered by DHTR.


2011201 51



Future BC Surveillance State

ALL FACILITIES


1. Recognize and report TR to TMS/Lab
2. Investigate
3. Reach a conclusion
4. Report to patient's chart
5. Send Transfusion Reaction reports to PBCO
6. Send serious Transfusion Reaction reports to CBS or manufacturer, as required



PBCO

1. Review cases for TTISS data elements.
2. Enter cases into PBCO database
3. Send non-nominal transfusion reaction BC data to national TTISS program
4. Report provincial and HA Transfusion Reaction data annually


2011201 52



Course Contributors – Advisory Panel

| Thanks to: | Health Authority | Advisory Group |
|-----------------------|------------------|----------------|
| Dr. Kate Chipperfield | VCH | TMAG |
| Dr. Jason Doyle | IH | TMAG |
| Dr. Doug Morrison | FH | TMAG |
| Dr. Louis Wadsworth | PHSA | TMAG |
| Maureen Wyatt | IH | TRG |
| Donna Miller | VIHA | NRG |
| Shelley Feenstra | VCH | NRG |

2011201 53



Acknowledgements

Sincere appreciation is due to the clinical, technical and pathologist representatives of the BC Health Authorities who contributed their knowledge, expertise, time or materials to the development of these modules.

Included are members of:


- BC Transfusion Medicine Advisory Group (TMAG)
- BC Transfusion Transmitted Injuries Surveillance System Working Group (BC TTISS WG)
- Technical Resource Group (TRG)
- Nursing Resource Group (NRG)

Development and secretariat support is provided by the BC Provincial Blood Coordinating Office (PBCO).

Funding for the support of transfusion reaction surveillance in BC is provided by the Public Health Agency of Canada (PHAC).

2011201 54

Questions?



2011201 55

Upcoming Live Webinars

| Date / Time | Topic | Speaker |
|--------------------------------------|--|---|
| December 15, 2011 12:00 to 1:00pm | Transfusion Reaction Annual Data Reports and Case Studies | Dr. Kate Chipperfield MD FRCPC Regional Medical Leader, Blood Transfusion Medicine, VCH |

2011201 56

Next Steps

- Visit LearningHub - [LearningHub Link](#)
- **Note:**
 - Need LearningHub Username and Password
 - Confirm email
- **Complete:**
 - Participant Evaluation
 - Quiz (**Closes midnight December 2, 2011**)

2011201 567
